Paul Verrastro Biography and Net Worth

Senior Advisor of CVRx

Paul Verrastro assumed the role of Senior Advisor in July 2026. Prior to this role, he served as the Company’s Chief Marketing and Strategy Officer from June 2022 to July 2026 and as Chief Marketing Officer from January 2021 to June 2022. He has over 34 years of experience in the cardiac rhythm market. Prior to joining the Company, Mr. Verrastro managed his own consulting business, working with clients such as St. Jude Medical, Abbott Cardiovascular and Medtronic CRDM. Mr. Verrastro started his career as a sales representative for Medtronic, and after ten years in the field, he joined Guidant Corporation as Director of Implantable Cardiac Defibrillators Marketing. Mr. Verrastro then served as Vice President of Marketing for all of Guidant Corporation in Europe and later as Vice President of Global Marketing for their customer relationship management division. In May 2011, Mr. Verrastro rejoined Medtronic as Vice President of Global Strategic Marketing. Over his career, he has helped bring a number of new technologies to market, including implantable cardiac defibrillators, cardiac resynchronization therapies, implantable loop recorders and leadless pacing. Mr. Verrastro received a B.S. degree from Syracuse University.

What is Paul Verrastro's net worth?: The estimated net worth of Paul Verrastro is at least $5.51 thousand as of November 19th, 2024. Mr. Verrastro owns 1,875 shares of CVRx stock worth more than $5,513 as of September 18th. This net worth evaluation does not reflect any other assets that Mr. Verrastro may own. Learn More about Paul Verrastro's net worth.
How do I contact Paul Verrastro?: The corporate mailing address for Mr. Verrastro and other CVRx executives is 9201 West Broadway Avenue, Suite 650, Minneapolis, MN, 55445. CVRx can also be reached via phone at (763) 416-2850 and via email at [email protected]. Learn More on Paul Verrastro's contact information.
Has Paul Verrastro been buying or selling shares of CVRx?: Paul Verrastro has not been actively trading shares of CVRx within the last three months. Most recently, Paul Verrastro sold 1,430 shares of the business's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $13.58, for a transaction totalling $19,419.40. Following the completion of the sale, the insider now directly owns 1,875 shares of the company's stock, valued at $25,462.50. Learn More on Paul Verrastro's trading history.
Who are CVRx's active insiders?: CVRx's insider roster includes Brent Binkowski (COO), Kevin Hykes ( President and CEO), Mudit Jain (Director), Kirk Nielsen (Director), and Paul Verrastro (Senior Advisor). Learn More on CVRx's active insiders.
Are insiders buying or selling shares of CVRx?: During the last twelve months, CVRx insiders bought shares 3 times. They purchased a total of 73,623 shares worth more than $376,740.93. During the last twelve months, insiders at the sold shares 7 times. They sold a total of 58,803 shares worth more than $586,749.47. The most recent insider tranaction occured on August, 13th when COO Brent Binkowski bought 26,223 shares worth more than $76,308.93. Insiders at CVRx own 16.6% of the company. Learn More about insider trades at CVRx.
Information on this page was last updated on 8/13/2026.

Paul Verrastro Insider Trading History at CVRx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/19/2024	Sell	1,430	$13.58	$19,419.40	1,875
2/20/2024	Sell	2,545	$21.91	$55,760.95	2,455
8/3/2023	Sell	628	$18.55	$11,649.40
7/31/2023	Sell	1,122	$17.49	$19,623.78	2,628
11/28/2022	Sell	4,600	$11.94	$54,924.00	4,400

Paul Verrastro Buying and Selling Activity at CVRx

CVRx Company Overview

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Today's Range

Now: $2.99

$2.92

$3.03

50 Day Range

MA: $3.83

$2.37

$5.94

2 Week Range

Now: $2.99

$2.20

$11.30

Volume

204,864 shs

Average Volume

497,715 shs

Market Capitalization

$79.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76